MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

20th International Congress » Parkinson's disease: Cognition

Date: Wednesday, June 22, 2016

Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Session Type: Poster Session

Meeting: 20th International Congress

12:00pm-1:30pm
A proposed Parkinson’s disease neuropsychological battery (PNB)

L.L. van Wanrooij, J. Hoogland, J.G. Goldman, G. Stebbins, G.J. Geurtsen, D. Weintraub (Amsterdam, Netherlands)

12:00pm-1:30pm
A technological solution for monitoring Parkinson’s disease: A patient-based perspective on necessity, usability and acceptability

S. Couth, E. Poliakoff, J. Vega, C. Jay, S. Harper, R. Almutiry, T.F. Cootes, A.M. Ramsay, S.A. Kotz (Manchester, United Kingdom)

12:00pm-1:30pm
Analysis of factors associated with cognitive and functional performance in Parkinsonian with normal mini-mental state examination

R. Breder, M.A.A. Leite, M.C.A. Ribas, M. Orsini (Niterói, Brazil)

12:00pm-1:30pm
Apolipoprotein E genotypes in Brazilian patients with Parkinson’s disease and their correlation with cognitive performance assessed by MoCA

M.M.C.M. Brito, R.S.J. Silva, V. Tumas, I.F. Mata, C.Z. Zabetian (Ribeirão Preto, Brazil)

12:00pm-1:30pm
Apraxia in Parkinson’s disease

M. Tábuas-Pereira, P. Correia, F. Moreira, A. Morgadinho, C. Januário (Coimbra, Portugal)

12:00pm-1:30pm
Are limbic and cognitive effects on balance in Parkinson’s disease equal?

K.A. Ehgoetz Martens, C.G. Ellard, Q.J. Almeida (Camperdown, Australia)

12:00pm-1:30pm
Arterial spin labeling perfusion MRI compensate for other diagnostic tools in evaluation of Parkinson’s disease with dementia

K. Abe, T. Hayashi, N. Akiyama, M. Yamamoto, M. Fujita (Nishinomiya, Japan)

12:00pm-1:30pm
Assessment of humor in Parkinson’s disease and the effect of deep brain stimulation

A. Greuel, C.J. Lewis, F. Maier, R. Dano, S. Heintz, W. Ruch, C. Eggers (Cologne, Germany)

12:00pm-1:30pm
Association between cognitive status and mobility performance in dual task condition in patients with Parkinson’s disease

S.M.A.A. Pompeu, T.B. Freitas, K.G. Silva, C. Torriani-Pasin, F. Doná, J.E. Pompeu (São Paulo, Brazil)

12:00pm-1:30pm
Association between urine protein/creatinine ratio and cognitive dysfunction in Parkinson’s disease

Y.S. Oh, J.S. Kim, K.S. Lee (Seoul, Korea)

12:00pm-1:30pm
Association or causation? Orthostatic hypotension and cognitive impairment in α-synucleinopathies: A systematic review

S.J. Udow, A.E. Lang, M. Masellis (Toronto, ON, Canada)

12:00pm-1:30pm
Attention and dopamine: Increased distractibility in Parkinson’s disease

C. Warden, S. YorkWilliams, N. Ahn, D. Everling, K.L. Poston (Stanford, CA, USA)

12:00pm-1:30pm
Baseline physical activity may influence exercise-induced changes in cognitive function in Parkinson’s disease

R. Chow, C.R.A. Silveira, B.N. Intzandt, E. Beck, Q.J. Almeida (Waterloo, ON, Canada)

12:00pm-1:30pm
Catechol-o-methyltransferase Val158Met polymorphism influences prefrontal executive function in early Parkinson’s disease

Y. Zhang, Y. Zhang, K. Nie, S. Feng, L. Wang, J. Zhao, Z. Huang, L. Wang (Guangzhou, People's Republic of China)

12:00pm-1:30pm
Cerebrospinal fluid biomarkers in Parkinson’s disease and associated cognitive impairment

M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, J. Ruiz-Martínez, A. Bergaretxe-Yarza, J.F. Martí-Massó, P. Martínez-Lage, A. Izagirre, A. Oregi, L. Sepúlveda, M.C. Rodríguez-Oroz (San Sebastián, Spain)

12:00pm-1:30pm
Characteristics of drop outs in a longitudinal study on individuals at risk for a neurodegenerative disorder

U. Suenkel, S. Heinzel, A.K. von Thaler, F. Metzger, G.W. Eschweiler, I. Liepelt-Scarfone, W. Maetzler, D. Berg (Tübingen, Germany)

12:00pm-1:30pm
Circulatory levels of BDNF correlate with cognitive deficits in people with Parkinson’s disease

H. Khalil, M.A. Alomari, O.F. Khabour, A. Al-Hieshan, J.A. Bajwa (Irbid, Jordan)

12:00pm-1:30pm
Cognition and amyloid biomarker status in non-demented patients with Parkinson’s disease patients (PD) with or without subjective cognitive decline (SCD)

I. Liepelt-Scarfone, F. Klumpp, W. Maetzler, S. Nussbaum, M. Timmers, G. Salvadore, M. Albers, K. Michaelis, Z. Tkaczynska, J. Streffer, D. Berg (Tübingen, Germany)

12:00pm-1:30pm
Cognitive and psychiatric outcome 3 years after bilateral deep brain stimulation of the globus pallidus pars interna versus subthalamic nucleus for Parkinson’s disease

J.A. Boel, V.J.J. Odekerken, G.J. Geurtsen, B.A. Schmand, M. Figee, R.J. de Haan, P. van den Munckhof, P.R. Schuurman, R.M.A. de Bie, The NSTAPS Study Group (Amsterdam, Netherlands)

12:00pm-1:30pm
Cognitive complaint in Parkinson’s disease patients with normal cognition

R.F. Purri, L. Brennan, J. Rick, L. Chahine, N. Dahodwala, A. Chen-Plotkin, J.E. Duda, J.F. Morley, R.S. Akhtar, J.Q. Trojanowski, D. Weintraub (Philadelphia, PA, USA)

12:00pm-1:30pm
Consolidation of learning and memory in Parkinson’s disease

M.E. Sharp, K. Duncan, K. Foerde, R. Kahane, D. Shohamy (New York City, NY, USA)

12:00pm-1:30pm
Construct validity of Moca test in a sample of patients with Parkinson´s disease in Bogotá and Cali – Colombia

B.E. Muñoz, O. Bernal, A. Castillo, J.L. Orozco (Cali, Colombia)

12:00pm-1:30pm
Cytokines in CSF and plasma as potential biomarkers for PD cognitive impairment

M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, J. Ruiz-Martínez, A. Bergaretxe-Yarza, J.F. Martí-Massó, P. Martínez-Lage, A. Izagirre, A. Oregi, L. Sepúlveda, M.C. Rodríguez-Oroz (San Sebastián, Spain)

12:00pm-1:30pm
Decline in drawing ability associated with frontal dysfunction after subthalamic nucleus deep brain stimulation in Parkinson’s disease

S. Hirano, S. Furukawa, M. Asahina, T. Yamamoto, T. Uchiyama, Y. Yamanaka, Y. Higuchi, T. Horikoshi, T. Uno, N. Saeki, S. Kuwabara (Chiba, Japan)

12:00pm-1:30pm
Defective visual perception in patients with Parkinson’s disease: The impairment of preattentive visual processing in the normal intellectual patients

Y. Higashi, T. Tabuchi, M. Tabata, E. Mori (Himeji, Japan)

12:00pm-1:30pm
Does cognitive decline contribute to poorer quality of life in incident Parkinson’s disease? A three year follow up

R.A. Lawson, A.J. Yarnall, G.W. Duncan, D.P. Breen, T.K. Khoo, C.H. Williams-Gray, R.A. Barker, D. Collerton, J.P. Taylor, D.J. Burn (Newcastle upon Tyne, United Kingdom)

12:00pm-1:30pm
Does repetitive transcranial magnetic stimulation (rTMS) affect cognitive function in Parkinson’s disease by modulating high-frequency brain oscillations: A magnetoencephalography (MEG) study

I. Buard, J. Shattuck, B.M. Kluger (Aurora, CO, USA)

12:00pm-1:30pm
Dopamine modulates learning conflicting action-valence associations in Parkinson’s disease

N.C. van Wouwe, D.O. Claassen, J.S. Neimat, S.A. Wylie (Nashville, TN, USA)

12:00pm-1:30pm
Dopaminergic drug management in Parkinson’s disease: Gait and language function show correlation during treatment

H. Murakami, A. Futamura, T. Kuroda, S. Ishigaki, M. Kezuka, K. Ono, M. Kawamura (Tokyo, Japan)

12:00pm-1:30pm
Dyskinesias-reduced-self-awareness and theory of mind in Parkinson’s disease: A novel frame of interpretation

S. Palermo, M. Amanzio, M. Zibetti, L. Lopiano (Turin, Italy)

12:00pm-1:30pm
Effect of rivastigmine in Parkinson’s disease dementia – A logitudinal observational study

S. Raha, L. Ebenezer (Bridgend, United Kingdom)

12:00pm-1:30pm
Effects of a 12-week exercise program on cognition in Parkinson’s disease

J.C. Johnson, A.L. Svitak, M.T. Farrell, S.C. Mosch, F. Yu, E.D. Parker, L.R. Hanson (Saint Paul, MN, USA)

12:00pm-1:30pm
Effects of gender, age and hyposmia on cognitive functions in healthy elderly individuals at risk for Parkinson’s disease: Results from the TREND study

S. Heinzel, U. Suenkel, F.G. Metzger, E. Schaeffer, B. Roeben, R. Yilmaz, S. Lerche, K. Brockmann, A.K. von Thaler, I. Liepelt-Scarfone, G.W. Eschweiler, A.J. Fallgatter, W. Maetzler, D. Berg (Tübingen, Germany)

12:00pm-1:30pm
Executive function and verbal fluency in patients with Parkinson’s disease

A.F. Barbosa, M.C. Voos, C.O. Souza, J. Chen, H.F. Chien, D.V. Francato, E.R. Barbosa, L.L. Mansur (São Paulo, Brazil)

12:00pm-1:30pm
Eye tracking-based measurement of cognitive functions in patients with neurodegenerative diseases

H. Schmitz-Peiffer, K. Linse, W. Rüger, M. Joos, M. Löhle, A. Storch, A. Hermann (Dresden, Germany)

12:00pm-1:30pm
Fall prediction in Parkinson’s disease based on motor dual-tasking: Evidence from the prospective MODEP study

S. Heinzel, M. Maechtel, S.E. Hasmann, M.A. Hobert, T. Heger, D. Berg, W. Maetzler (Tübingen, Germany)

12:00pm-1:30pm
Functional connectivity during resting state in Parkinson’s disease patients with and without mild cognitive impairment

O. Monchi, A. Nagano-Saito, A. Hanganu, S. Jobert, B. Mejia-Constain, C. Degroot, A.L. Lafontaine, H. Chertkow, A. Tam, P. Orban, P. Bellec, O. Monchi (Calgary, AB, Canada)

12:00pm-1:30pm
Gait and cognition: Mapping the global and discrete relationships in ageing and neurodegenerative disease

R. Morris, S. Lord, J. Bunce, D. Burn, L. Rochester (Newcastle-Upon-Tyne, United Kingdom)

12:00pm-1:30pm
Genetic factors influencing frontostriatal dysfunction and the development of dementia in Parkinson’s disease

I. Huertas Fernandez, S. Jesus, F.J. Garcia Gomez, J.A. Lojo, I. Bernal Bernal, M. Bonilla Toribio, J.F. Martin Rodriguez, D. Garcia Solis, P. Gomez Garre, P. Mir (Sevilla, Spain)

12:00pm-1:30pm
Grey matter atrophy associated with the progression of cognitive decline in Parkinson’s disease (PD)

M. Chondrogiorgi, L.G. Astrakas, A.K. Zikou, M.I. Argyropoulou, S. Konitsiotis (Ioannina, Greece)

12:00pm-1:30pm
How do cognitive profiles differ in patients with Parkinson’s disease with cognitive decline in comparison to patients remaining cognitively stable? Preliminary results of a 3 years follow-up study

A. Meyer, U. Gschwandtner, V. Cozac, F. Hatz, P. Fuhr (Basel, Switzerland)

12:00pm-1:30pm
How does cognition affect reaching in Parkinson’s disease?

J. Cosgrove, C. Picardi, S.L. Smith, S. Jamieson, J.E. Alty (Leeds, United Kingdom)

12:00pm-1:30pm
Imitation of hand movements in Parkinson’s disease: A comparison with visual cueing

J. Bek, E. Gowen, S. Vogt, T. Crawford, E. Stack, J. Dick, E. Poliakoff (Manchester, United Kingdom)

12:00pm-1:30pm
Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists

M.E. Mohammad, J.A. Vizcarra, K. O'Donnell, S. Patel, X. Garcia, X.X. Yu, K. Vlastaris, K. Sutton, H.H. Fernandez (Cleveland, OH, USA)

12:00pm-1:30pm
Impact of sociodemographic and clinical characteristics on cognition of individuals with Parkinson’s disease

M.R. Olchik, A. Ayres, M. Ghisi, A.F.S. Schuh, C.R.M. Rieder (Porto Alegre, Brazil)

12:00pm-1:30pm
Impaired cube copy on the MOCA indicates worse performance in several cognitive domains in Parkinson´s disease

C. Gasca-Salas, M. Cohn, J.A. Pineda, J.A. Obeso (Madrid, Spain)

12:00pm-1:30pm
Impairment of decision-making processes in patients with Parkinson’s disease during a strategic game

A.C. Parr, B.C. Coe, G. Pari, D.P. Munoz (Kingston, ON, Canada)

12:00pm-1:30pm
Interrelation between gait impairment with cognitive disturbances in patients with Parkinson’s disease

K. Stepanchenko (Kharkiv, Ukraine)

12:00pm-1:30pm
Investigating the relationship between reaction time and cognition in Parkinson’s disease

J. Cosgrove, C. Picardi, S.L. Smith, S. Jamieson, J.E. Alty (Leeds, United Kingdom)

12:00pm-1:30pm
Investigation of driving ability to drive safely in patients with Parkinson’s disease by interview

R. Ando, C. Yamazaki, H. Iwaki, H. Yabe, N. Nishikawa, M. Nagai, K. Nakashima, M. Nomoto, Safe Driving Study Group of Japan (Tohon, Japan)

12:00pm-1:30pm
Longterm outcome of cognition following subthalamic deep brain stimulation in Parkinson´s disease

D. Gruber, C. Lisa, A. Kuehn, U. Kopp, G.H. Schneider, A. Kupsch (Beelitz-Heilstätten, Germany)

12:00pm-1:30pm
Mild cognitive impairment in Parkinson’s disease: Impact on caregiver outcomes

J.Y.Y. Szeto, M. Gilat, C.C. Walton, L. Mowszowski, S.L. Naismith, S.J.G. Lewis (Sydney, Australia)

12:00pm-1:30pm
Neuro-cognitive domain related to conversion of Parkinson’s disease dementia

S.M. Cheon, S.Y. Lee, J.W. Kim (Busan, Korea)

12:00pm-1:30pm
Neuron specific protein S100B and cognitive impairment in various forms parkinsonism

R.J. Matmurodov, K.M. Khalimova, N.S. Rashidova, U. Ergashev, O. Turgunhojayev (Tashkent, Uzbekistan)

12:00pm-1:30pm
Neuropsychological subgroups in non-demented Parkinson’s disease: A latent class analysis

L. Brennan, K. Devlin, S.X. Xie, D. Mechanic-Hamilton, B. Tran, H. Hurtig, A. Chen-Plotkin, L. Chahine, J.F. Morley, J.E. Duda, D.R. Roalf, N. Dahodwala, J. Rick, J.Q. Trojanowski, P.J. Moberg, D. Weintraub (Philadelphia, PA, USA)

12:00pm-1:30pm
Occurrence and pattern of cognitive deficits in prodromal Parkinson’s disease

C. Pausch, J. Spiegel, F.A. Wollenweber, C. Bayer, U. Dillmann, K. Fassbender, S. Behnke (Homburg Saar, Germany)

12:00pm-1:30pm
Optic nerve integration as a visuospatial cognitive predictor in Parkinson’s disease

J.J. Lee, Y. Lee, S.J. Chung, Y.H. Sohn, P.H. Lee (Seoul, Korea)

12:00pm-1:30pm
Participation in cognitively-stimulating activities and computer use are associated with better cognitive performance in Parkinson’s disease independent from nigrostriatal dopaminergic and cortical cholinergic degenerations

J.L.B. Bohnen, M.L.T.M. Muller, J.D.J. Haugen, N.I. Bohnen (Ann Arbor, MI, USA)

12:00pm-1:30pm
Perception of time in music in Parkinson´s disease – Processing of musical syntax compensates rhythmic deficits

D. Bellinger, E. Altenmüller, J. Volkmann (Wuerzburg, Germany)

12:00pm-1:30pm
Performance in Montreal cognitive assessment and functional independence in Parkinsonian with normal mini-mental state examination

R. Breder, M.A.A. Leite, B.L. Pessoa, C.O. Vilaça (Niterói, Brazil)

12:00pm-1:30pm
Piperine potentiates neuroprotective effect of curcumin in MPTP model of Parkinson’s disease in rats: Impact on neurochemical modulation

S. Singh, P. Kumar (Moga, India)

12:00pm-1:30pm
Predictive performance of EEG theta spectral power over developing dementia in Parkinson’s disease

V.V. Cozac, M. Chaturvedi, U. Gschwandtner, F. Hatz, A. Meyer, K. Nowak, R. Sturzenegger, P. Fuhr (Basel, Switzerland)

12:00pm-1:30pm
Predictors of dementia in Parkinson’s disease: A population-based cohort study

A. Keener, K. Paul, A. Folle, J. Bronstein, B. Ritz (Los Angeles, CA, USA)

12:00pm-1:30pm
Rapid eye movement sleep behavior disorder symptoms correlate with domains of cognitive impairment in Parkinson’s disease

J.R. Zhang, J. Chen, Z.J. Yang, H.J. Zhang, Y.T. Fu, Y. Shen, P.C. He, C.J. Mao, C.F. Liu (Suzhou, People's Republic of China)

12:00pm-1:30pm
Reliability of verbal and written trail test for individuals with Parkinson’s disease: Is it a good cognitive test?

M.R. Olchik, M. Ghisi, A. Freiry, A.F.S. Schuh, C.R.M. Rieder (Porto Alegre, Brazil)

12:00pm-1:30pm
Response inhibition in Parkinson’s disease

J. Kim, K. Zhang, M.A.I.U.A. Cruadhlaoich, S. YorkWilliams, V. Menon, K.L. Poston (Stanford, CA, USA)

12:00pm-1:30pm
Retrieval action verbs is impaired in Parkinson´s disease patients using a sentence completion task

E. Herrera, R. Pérez, M. González-Nosti (Gijón, Spain)

12:00pm-1:30pm
Scores and dimensions to assess cognitive impairment in Parkinson’s disease

I. Liepelt-Scarfone, S. Gräber, A. Pilotto, D. Blum, M. Fruhmann Berger, D. Berg (Tübingen, Germany)

12:00pm-1:30pm
Screening of posterior cortical dysfunction in early Parkinson’s disease with mild cognitive impairment as an approach to select patients at higher risk for developing dementia

H. Bejr-Kasem, J. Pagonabarraga, R. Fernandez-Bobadilla, J. Perez-Perez, J. Marin-Lahoz, B. Pascual-Sedano, S. Martínez-Horta, J. Kulisevsky (Barcelona, Spain)

12:00pm-1:30pm
Self-reported cognitive complaints and neuropsychological performance in idiopathic REM sleep behavior disorder

P.A. Bourgouin, F. Escudier, L. Bernier-Lalonger, R.B. Postuma, J. Montplaisir, J.F. Gagnon (Montreal, QC, Canada)

12:00pm-1:30pm
Sensitivity of people with Parkinson’s to different intensities of emotions (SPiEs)

J. Wincenciak, D.J. Burn, L.S. Delicato (Newcastle upon Tyne, United Kingdom)

12:00pm-1:30pm
Single-subject FDG PET patterns and cognitive dysfunctions in Parkinson’s disease

A. Pilotto, E. Premi, S.P. Caminiti, L. Presotto, R. Turrone, A. Alberici, B. Paghera, B. Borroni, D. Perani, A. Padovani (Brescia, Italy)

12:00pm-1:30pm
Speech prosody impairment predicts cognitive decline in Parkinson’s disease

I. Rektorova, J. Mekyska, E. Janousova, M. Kostalova, M. Mrackova, I. Eliasova, D. Berankova, R. Marecek (Brno, Czech Republic)

12:00pm-1:30pm
Staging of cognitive impairment: Validation of a novel cognitive score with [18F]FDG-PET

D. Blum, M. Reimold, W. Maetzler, C. la Fougère, G. Reischl, D. Berg, I. Liepelt-Scarfone (Tübingen, Germany)

12:00pm-1:30pm
Synaptic biomarkers for cognitive decline in Lewy body dementias and Alzheimer’s disease. A mass spectrometry approach

E. Bereczki, R.M.M. Branca, P.T. Francis, J.H. Baek, J. Lehtio, D. Aarsland (Huddinge, Sweden)

12:00pm-1:30pm
Temporal working memory deficit in Parkinson’s disease

B. Degos, I. Ameqrane, S. Rivaud-Péchoux, P. Pouget, M. Missal (Paris, France)

12:00pm-1:30pm
The alterations in behavioral memory for prolongation disease duration in patients with Parkinson’s disease

M. Saruwatari, Y. Kobayashi, A. Kumon, K. Hasegawa (Sagamihara, Japan)

12:00pm-1:30pm
The cognitive profile of idiopathic REM sleep behavior disorder

L. Bernier-Lalonger, F. Escudier, P.A. Bourgouin, R.B. Postuma, J. Montplaisir, J.F. Gagnon (Montreal, QC, Canada)

12:00pm-1:30pm
The effect of anodal transcranial direct current stimulation (tDCS) on sequential motor skill learning in persons with Parkinson’s disease

E. Kerckhofs, N. Deroost (Brussels, Belgium)

12:00pm-1:30pm
The effect of statin use on cognition in Parkinson’s disease

B.L. Deck, J. Rick, S.X. Xie, A. Chen-Plotkin, J.E. Duda, J.F. Morley, L.M. Chahine, N. Dahodwala, R.S. Akhtar, J.Q. Trojanowski, D. Weintraub (Philadelphia, PA, USA)

12:00pm-1:30pm
The effects of deep brain stimulation for Parkinson’s disease on cognition and perceived quality of life: Preliminary results from an Ecuadorian sample

M.B. Jurado Noboa, R. Santibañez Vásquez, J. Achi, M. Navarrete, C. Mawyin (Guayaquil, Ecuador)

12:00pm-1:30pm
The relationship between cognitive aspects (education status, executive function and verbal fluency) and motor aspects (balance and gait) in patients with Parkinson’s disease

C.O. Souza, M.C. Voos, H.F. Chien, D.V. Francato, A.F. Barbosa, J.M. Greve, E.T. Fonoff, E.R. Barbosa (Sao Paulo, Brazil)

12:00pm-1:30pm
The role of neuroinflammation in the development of Parkinson’s disease dementia

A. Kouli, R. Vuono, R.A. Barker, C.H. Williams-Gray (Cambridge, United Kingdom)

12:00pm-1:30pm
Transcranial sonography and cognitive dysfunction in Parkinson’s disease

S. Behnke, A. Pilotto, I. Liepelt-Scarfone, R. Yilmaz, C. Pausch, S. Dieterich, I. Posner, J. Spiegel, U. Dillmann, M. Unger, B. Schmidl, J. Bürmann, K. Fassbender, D. Berg (Homburg Saar, Germany)

12:00pm-1:30pm
Treatment and diagnosis with the use of neuropsychological scale in patients with posttraumatic subcortical Parkinsonian dementia

R.R. Umarov, N.G. Sokhibnazarov (Tashkent, Uzbekistan)

12:00pm-1:30pm
Treatment with the use of the PD-specific scales for patients suffering from subcortical Parkinsonian dementia

N.G. Sokhibnazarov, F.K. Shermukhamedova (Tashkent, Uzbekistan)

12:00pm-1:30pm
Unilateral subthalamotomy in Parkinson´s disease: Cognitive and neuropsychiatric effects and correlation with lesion size

I. Obeso, E. Casabona, R. Rodríguez-Rojas, N. Pavón, R. Macías, M.L. Bringas, J.A. Obeso, M. Jahanshahi (Madrid, Spain)

12:00pm-1:30pm
Use of dementia rating scale-II (DRS-II) total score in PD deep brain stimulation (DBS) candidacy determination

M.J. Sollman, J.G. Hesse, B.C. Sachs, J.F. Cook (Winston-Salem, NC, USA)

12:00pm-1:30pm
Validation of the Seoul-instrumental activity of daily living in the detection of dementia in Parkinson’s disease

S.J. Kim, E.J. Chung (Busan, Korea)

12:00pm-1:30pm
Visual hallucinations may serve as a possible predictor for Parkinson’s disease dementia

Y.P. Chang, Y.H. Yang, C.L. Lai, L.M. Liou (Kaohsiung, Taiwan)

« View all sessions from the 20th International Congress.

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley